Target and Dell Are Among the Biggest Decliners
This morning, the breakdown in shares of Target (TGT) might continue. The company posted second-quarter results that beat expectations. But markets did not like the new Chief Executive Officer choice.Target posted a 0.9% drop Y/Y in revenue, to $25.21 billion. Net sales of $25.2 billion, a 0.9% fall Y/Y, are a result of merchandise sales falling by 1.2%. Still, non-merchandise sales rose by 14.2%.Investors did not like the company picking Michael Fiddelke as the next CEO. The internal candidate suggested that Target will not change its struggling business strategy.Dell Technologies (DELL) erased the summer’s gain by falling by 5% yesterday. DELL stock is relatively inexpensive at a 20 times price-to-earnings ratio. The valuation is attractive, yet any panic selling in the tech sector would hurt DELL stock even more.Value investors found prospective picks in the tech space. HP Inc. (HPQ) trades at a 10.2 times P/E. The stock formed a narrow uptrend since June, rising from $24 to close at $26.47. Hewlett-Packard Enterprise (HPE) bottomed at $11.97 in April and closed at $21.04. At a 21.7 times P/E, HPE stock is fully valued.Investors who want value companies with a bigger market capitalization may consider Cisco Systems (CSCO), Taiwan Semiconductor (TSM), ASML Holding (ASML), and Uber (UBER).
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


